Bombshell Document Dump on Pfizer Vaccine Data
All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).
To receive Global Research’s Daily Newsletter (selected articles), click here.
Visit and follow us on Instagram at @crg_globalresearch.
First published on December 5, 2021
***
Have you seen the document dump on the Pfizer vaccine data? It’s a bombshell. No wonder the FDA fought to keep it hidden for 55 years.
Here is the quick takeaway:
By February of 2021, Pfizer had already received more than 1,200 reports of deaths allegedly caused by the vaccine and tens of thousands of reported adverse events, including 23 cases of spontaneous abortions out of 270 pregnancies and more than 2,000 reports of cardiac disorders.
Bear in mind, this is Pfizer’s own data.
Election Wizard
Our thanks to the Election Wizard for bringing this report to our attention.
***
Global Research Editor’s Note
This report provides the data on deaths and adverse events recorded by Pfizer from the outset of the vaccine project in December 2020 to the end of February 2021, namely a very short period (at most two and a half months).
The Pfizer BioNTech vaccine was launched in the US on the 14th of December after the granting of Emergency Use Authorization on December 11, 2020.
What is contained in Pfizer’s confidential report is detailed evidence on the impacts of the “vaccine” on mortality and morbidity. This data which emanates from the “Horse’s Mouth” can be used to confront as well formulate legal procedures against Big Pharma, the governments, the WHO and the media.
Bear in mind: it’s data which is based on reported and recorded cases, which constitute a small percentage of the actual number of vaccine related deaths and adverse events.
This is a de facto Mea Culpa on the part of Pfizer. #Yes it is a Killer Vaccine
“Killing is Good for Business”: It is a multibillion dollar operation worldwide.
We invite the “Covid-19 Fact Checkers” to peruse this Pfizer report.
Selected excerpts, tables and diagram provided below
Michel C. Global Research, December 5, 2021
***
Click here to read Pfizer’s report.
also details in the Appendices
Selected Excerpts of the Report
This document provides an integrated analysis of the cumulative post-authorization safety data, including U.S. and foreign post-authorization adverse event reports received through 28 February 2021.
(…)
Pfizer is responsible for the management post-authorization safety data on behalf of the MAH BioNTech according to the Pharmacovigilance Agreement in place. Data from BioNTech are included in the report when applicable.
Reports are submitted voluntarily, and the magnitude of underreporting is unknown.
(…)
Cumulatively, through 28 February 2021 [in less than three months], there was a total of 42,086 case reports (25,379 medically confirmed and 16,707 non-medically confirmed) containing 158,893 events. Most cases (34,762) were received from United States (13,739), United Kingdom (13,404) Italy (2,578), Germany (1913), France (1506), Portugal (866) and Spain (756); the remaining 7,324 were distributed among 56 other countries.
(…)
As shown in Figure 1 [see below], the System Organ Classes (SOCs) that contained the greatest number (≥2%) of events, in the overall dataset, were General disorders and administration site conditions (51,335 AEs), Nervous system disorders (25,957), Musculoskeletal and connective tissue disorders (17,283), Gastrointestinal disorders (14,096), Skin and subcutaneous tissue disorders (8,476), Respiratory, thoracic and mediastinal disorders (8,848), Infections and infestations (4,610), Injury, poisoning and procedural complications (5,590), and Investigations (3,693
emphasis added
*
Note to readers: Please click the share buttons above or below. Follow us on Instagram, @crg_globalresearch. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.
Featured image is from BigPharmaNews.com
Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca
www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.
For media inquiries: publications@globalresearch.ca
No comments:
Post a Comment